Lilly fighting back on compounded Mounjaro and Zepbound

16 May 2024

US pharma major Eli Lilly (NYSE: LLY) has provided an update on compounding litigation relating to tirzepatide, its drug for type 2 diabetes and weight loss that is marketed as Mounjaro and Zepbound.

Following a series of lawsuits that the company filed in September and October 2023, Lilly has entered into a settlement agreement requiring defendant Totality Medispa to make a monetary payment and prohibiting it from engaging in certain conduct.

"This is not a problem that Lilly can solve alone"Lilly says that its settlement will stop Totality Medispa from misleading consumers into believing that it is selling Mounjaro or Zepbound approved by the US Food and Drug Administration (FDA), that its compounded products have been the subject of clinical tests, or that its compounded medicines have been proven safe and effective to achieve certain clinical results.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK